Featured news from NHIVNA
HIV-related news from NAM
New antiretrovirals and HIV treatment strategies highlighted at ICAAC
Liz Highleyman, 2015-10-07 10:30:00
Researchers presented findings from several HIV studies at the 55th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) last week in San Diego, USA, including an overview of the START treatment initiation study, an all-women antiretroviral therapy trial, studies of a better tolerated version of tenofovir and news about integrase inhibitors.
ICAAC was once one of the major annual venues for the presentation of HIV and AIDS treatment research, but this has become less of a focus now that antiretroviral therapy (ART) is highly effective and generally well-tolerated. This year's conference, jointly organised by the American Society for Microbiology and the International Society of Chemotherapy, was the last under the ICAAC name; next year it will be incorporated into the new ASM Microbe 2016 meeting.
HIV presentations at ICAAC 2015 included a symposium reviewing 'What’s New in Antiretroviral Therapy', an International AIDS Society-USA interactive session on 'Challenges and Complexities in Managing HIV Infection', a symposium on HIV prevention, and oral slide sessions on new antiretroviral drugs and strategies and HIV-associated comorbidities.
Source:1
